Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Weekly Portfolio Update

|About: Abeona Therapeutics Inc. (ABEO), BLCM, Includes: ADMS, FOLD, GILD, JAZZ, KITE, LOXO, MNK, MRSN, SRPT, TRVN

Summary

As of the market close on Friday, my portfolio is up 12.11% on weekly basis, above the return of 9.27% from my benchmark NQ US Sm Cap Biotech Index.

I have to say that NQ US Sm Cap Biotech Index is really challenging as a benchmark.

Of the current 9 stocks in the portfolio, 7 stocks are up, 2 (NASDAQ:JAZZ)(NASDAQ:TRVN) are flat (±3%).

We almost hit 300K this week :)

The FDA designates Abeona Therapeutics' (NASDAQ:ABEO) Orphan Drug-tagged EB-101, a Breakthrough Therapy for the treatment of epidermolysis bullosa. ABEO shares up more than 40% since added to my portfolio. I've decided to take profits on ABEO.

CAR-T developer Bellicum Pharmaceuticals (NASDAQ:BLCM) is up after Gilead's announced $11.9B takeover of Kite Pharma. Its lead candidate is Phase 1/2-stage BPX-501. Shares up almost 40% since added to my portfolio. I've decided to take profits on BLCM.

With the cash coming from BLCM and ABEO I go for Amicus (NASDAQ:FOLD) and increase my holdings. 

My Portfolio has been updated with today's closing prices.